Short Squeeze Setup — velZ +0.54 · age 21w×1.00 · 19.05%
Seasonal Tailwind — november med 7.7% (mag 2/3) · posClose 72.73% (rel 2/3) · n11 ×0.75 = 6
Founder-Led — founder/CEO led
About Kura Oncology Inc
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a… Read full Trend Edge analysis →
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
IPO Date: September 22, 2015
Headquarters: 4930 Directors Place, San Diego, CA, United States, 92121
Founder-Led: Yes — Troy Wilson (Chairman, CEO & President)
Key Metrics
Current Price
$10.60
Market Cap
$936M
Float
70.5M
Shares Outstanding
89.0M
Price/Sales (TTM)
12.12
vs. Analyst Target
+200.4% to analyst PT
Operating Margin (TTM)
-349.77%
Revenue (TTM)
$77.2M
Dividend Rate
None
Analyst Target Price
$31.85 (16 analysts)
Financial History
Annual Revenue & Earnings History
Year
Revenue
Net Income
Gross Profit
EBITDA
2020
N/A
-$89.6M
-$194,000
-$88.9M
2021
N/A
-$130M
-$558,000
-$129M
2022
N/A
-$136M
-$759,000
-$135M
2023
N/A
-$153M
-$849,000
-$150M
2024
$53.9M
-$174M
$53.9M
-$169M
2025
$67.5M
-$279M
$67.4M
-$276M
Recent Quarterly Revenue & Net Income
Quarter
Revenue
Net Income
Sep 2025
$20.8M
-$74.1M
Dec 2025
$17.3M
-$81.0M
Mar 2026
$18.3M
-$73.3M
Jun 2026
$20.9M
-$68.3M
Ownership & Float
Insider Ownership
1.4%
Institutional Ownership
100.1%
Short Float
19.0%
% of All Funds Holding
2.50%
Number of Funds Holding
220
Current Moving Averages
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
Timeframe
SMA
Value
Trend Context
Weekly
10-Week SMA
$11.34
Near-term / short-term trend
Weekly
40-Week SMA
$9.79
Medium-term trend
Weekly
80-Week SMA
$8.86
Cyclical trend (business cycle)
Weekly
200-Week SMA
$11.97
Secular trend (multi-year)
Monthly
10-Month SMA
$9.79
Near-term monthly trend
Monthly
20-Month SMA
$8.91
Medium-term monthly trend
Monthly
40-Month SMA
$11.93
Secular monthly trend
Volume Shelves — Support & Resistance
Trend Edge identifies volume shelves: price zones where historically elevated trading volume
creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative
volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Price Level
Type
Volume Ratio
Age
$12.50
resistance
1.11x
0 months ago
$9.10
support
1.34x
1 months ago
$8.80
support
1.09x
4 months ago
$6.00
support
1.23x
13 months ago
$16.70
resistance
2.67x
22 months ago
Historical Earnings Reactions (44 events)
Timeframe
Avg Return
Median
Win Rate
Best
Worst
Gap
0.97%
-0.09%
47.73%
49.54%
-7.33%
1 Day
-0.09%
-0.56%
38.64%
20.18%
-13.04%
1 Week
1.68%
0.94%
61.36%
32.94%
-41.55%
2 Weeks
0.30%
1.00%
52.27%
32.60%
-39.22%
1 Month
1.93%
2.21%
53.49%
49.61%
-42.60%
Next earnings: November 3, 2026 (23 days away)
Seasonality & Day-of-Week Patterns
Monthly Seasonality
Month
Avg Return
Win Rate
Samples
Jan
0.2%
54.5%
11
Feb
3.2%
54.5%
11
Mar
-3.3%
54.5%
11
Apr
-2.1%
27.3%
11
May
2.8%
54.5%
11
Jun
4.1%
54.5%
11
Jul
1.8%
45.5%
11
Aug
9.7%
54.5%
11
Sep
9.6%
45.5%
11
Oct
-5.7%
36.4%
11
Nov
0.1%
72.7%
11
Dec
0.4%
45.5%
11
Day-of-Week Tendencies
Day
Avg Return
Win Rate
Samples
Monday
-0.01%
45.8%
520
Tuesday
0.03%
46.7%
572
Wednesday
-0.03%
47.3%
569
Thursday
0.18%
49.6%
560
Friday
0.26%
46.3%
557
Top Institutional Holders
Institutional holder breakdown coming soon.
Total institutional ownership: 100.1%
Insider Transactions — Smart Summary
Total insider ownership: 1.4%
Founder-led management: Troy Wilson (Chairman, CEO & President)
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Kura Oncology Inc
(KURA) powered by Claude Opus — Anthropic's most capable AI model.
The analysis covers five layers:
technical analysis (near-term, medium-term, cyclical, and secular trend, momentum,
volume shelf support and resistance, breakout and breakdown signals),
qualitative analysis (business model, competitive moat, sector dynamics),
insider sentiment (buy and sell signals from executive and director transactions),
share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and
fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit,
stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward.
Whether you are building a long position, initiating a short, or looking for a reversal setup,
AI Consult identifies the highest-probability signal from the current trend.